随着2024年及2025年一季度财报的披露,国内医药行业迎来振奋人心的消息。多家药企凭借核心大单品实现业绩快速增长。百济神州的泽布替尼在2025年一季度全球销售额达56.92亿元,同比增长63.7%,特别是在美国市场表现突出。百济神州一季度营收80.48亿元,同比增长50.2%,归母净亏损大幅收窄。再鼎医药一季度总营收1.065亿美元,同比增长22%,经营亏损同比收窄20%。康方生物得益于卡度尼利...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.